{
    "nct_id": "NCT04896697",
    "official_title": "A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors",
    "inclusion_criteria": "Disease Criteria -\n\n* Part 1A and 1C: Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard therapy, or standard therapy is not curative or available;\n* Part 1B:\n\n  * Any histologically or cytologically confirmed solid tumor malignancy for which anti-PD-1 or anti-PD-L1 treatment is approved and has progressed on or after prior anti-PD-1 or anti-PD-L1 therapy.\n  * Patients with metastatic castrate-resistant prostate cancer if they have progressed on at least 2 lines of systemic therapy\n  * Patients with extensive stage small cell lung cancer (SCLC) after at least 1 line of prior therapy\n  * Patients with microsatellite stable colorectal cancer after at least 2 lines of prior therapy\n* Phase 2: Patients with histologically confirmed metastatic MSS CRC are eligible to enroll in Phase 2 as follows:\n\n  * Patients must have had at least 1 prior chemotherapy regimen for metastatic CRC including all of the following agents: a fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab or biosimilars, an anti epidermal growth factor receptor antibody (cetuximab or panitumumab), and v-raf murine sarcoma viral oncogene homolog B1 inhibitor/BRAF (encorafenib), if applicable\n  * Patients with MSI-H/dMMR are excluded\n* ECOG performance status of 0 or 1\n* Adequate organ function\n* Part 1B, Part 1C, and Phase 2 only: measurable disease per iRECIST\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received prior treatment with anti-CTLA-4 therapy\n* Received prior immune-checkpoint therapy and experienced Grade 3 or greater toxicity lasting greater than 6 weeks\n* Received prior systemic anticancer therapy within 4 weeks prior to study treatment\n* Received prior radiotherapy within 2 weeks prior to study treatment\n* Phase 2 only: Received prior anti-PD-1/L1 therapy or any investigational checkpoint inhibitory therapy\n* Has a diagnosis of immunodeficiency\n* Has known malignancy (other than disease under study) that is progressing or has required active treatment within the past 3 years\n* Has an active autoimmune disease that has required systemic treatment in past 2 years, including the use of disease modifying agents, corticosteroids or immunosuppressive drugs\n* Has an active infection requiring systemic intravenous therapy within 4 weeks prior to study treatment, or oral therapy within 2 weeks prior to study treatment\n* Has a history of severe hypersensitivity reaction (â‰¥ Grade 3) to any study intervention and/or any of its excipients\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study\n* Phase 2 only: symptomatic bowel obstruction",
    "miscellaneous_criteria": ""
}